Concepedia

Robert Orlowski

RO

23

Publications

2.2K

Citations

17

H-Index

2018

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Eisai (United States)

Memorial Sloan Kettering Cancer Center

Saitama Medical University

Hospital Clínico San Carlos

Robert Orlowski is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, oncology, and cancer therapeutics.

ORCID

Top concepts

Publications per year

2018–2024

23

Publications

23

A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma

Alexander C. Huang, Robert Orlowski, Xiaowei Xu et al. · Nature Medicine · 2019 · 683 citations

, , +11

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer

Vicky Makker, Matthew H. Taylor, Carol Aghajanian et al. · Journal of Clinical Oncology · 2020 · 512 citations · Full text

Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma

Philippe Armand, Scott J. Rodig, Catherine Thiéblemont et al. · Journal of Clinical Oncology · 2019 · 256 citations · Full text

Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775

Vicky Makker, Nicoletta Colombo, Antonio Casado et al. · Journal of Clinical Oncology · 2023 · 123 citations · Full text

PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell–inflamed phenotype

James Godfrey, Sravya Tumuluru, Riyue Bao et al. · Blood · 2019 · 120 citations · Full text

Rows per page

1–5 of 23